Therapeutic HIV Peptide Vaccine

Anders Fomsgaard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Therapeutic vaccines aim to control chronic HIV infection and eliminate the need for lifelong antiretroviral therapy (ART). Therapeutic HIV vaccine is being pursued as part of a functional cure for HIV/AIDS. We have outlined a basic protocol for inducing new T cell immunity during chronic HIV-1 infection directed to subdominant conserved HIV-1 epitopes restricted to frequent HLA supertypes. The rationale for selecting HIV peptides and adjuvants are provided. Peptide subunit vaccines are regarded as safe due to the simplicity, quality, purity, and low toxicity. The caveat is reduced immunogenicity and hence adjuvants are included to enhance and direct the immune response. Although the vaccine has been tested in ART naïve individuals, we recommend future testing of the vaccine during (early started) ART that improves immune function and to select individuals likely to benefit. Peptides representing other epitopes may be used.

TidsskriftMethods in Molecular Biology
Sider (fra-til)351-357
Antal sider7
StatusUdgivet - 2015

Fingeraftryk Dyk ned i forskningsemnerne om 'Therapeutic HIV Peptide Vaccine'. Sammen danner de et unikt fingeraftryk.